Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CarlsmedFRA:I82 12 3-1 Month Momentum % is 25.13% as of Sep. 10, 2026. GuruFocus rates FRA:I82 with a GF Score™ of 12/100. The stock has 1 warning sign investors should review. Among 663 Healthcare Providers & Services companies, Carlsmed ranks better than 88.08% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-09-10), Carlsmed's 3-1 Month Momentum % is 25.13%.
The industry rank for Carlsmed's 3-1 Month Momentum % or its related term are showing as below:
FRA:I82's 3-1 Month Momentum % is ranked better than 88.08% of 663
companies
in the Healthcare Providers & Services industry
Industry Median: 1.76
vs FRA:I82: 25.13
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Carlsmed 3-1 Month Momentum % Related Terms
FRA:I82 vs NRC, EVH, SLP: 3-1 Month Momentum % Comparison
For the Health Information Services subindustry, Carlsmed's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Carlsmed 3-1 Month Momentum % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Carlsmed's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Carlsmed's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Carlsmed (FRA:I82) has a 3-1 Month Momentum % of 25.13% as of Sep. 10, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Carlsmed and its competitors. According to the industry distribution chart, Carlsmed ranks #79 out of 663 companies in the Healthcare Providers & Services industry, placing it in the top 11.9%.
Is Carlsmed's 3-1 Month Momentum % too high?
Carlsmed's current 3-1 Month Momentum % is 25.13%. The Healthcare Providers & Services industry median 3-1 Month Momentum % is 1.76. Carlsmed's value of 25.13% is 1327.8% above this industry median. Based on the distribution chart, Carlsmed ranks #79 out of 663 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Carlsmed has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Carlsmed's 3-1 Month Momentum % compare to NRC and EVH?
According to the Healthcare Providers & Services industry distribution chart, Carlsmed ranks #79 out of 663 companies for 3-1 Month Momentum %. This places Carlsmed in the top 12% of its industry — outperforming the majority of peers. The industry median 3-1 Month Momentum % is 1.76. Carlsmed's value of 25.13% is 1327.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Healthcare Providers & Services company?
The median 3-1 Month Momentum % among Healthcare Providers & Services companies is 1.76, based on 663 companies in the industry. Companies in the top quartile (top 25%) have a 3-1 Month Momentum % significantly above this median, while those in the bottom quartile fall well below. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Carlsmed's current 3-1 Month Momentum % of 25.13% is 1327.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Carlsmed and its competitors. For the Healthcare Providers & Services industry, the median 3-1 Month Momentum % is 1.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Carlsmed's current 3-1 Month Momentum % is 25.13%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Carlsmed stock overvalued right now?
Carlsmed (FRA:I82) has a current 3-1 Month Momentum % of 25.13%. The current 3-1 Month Momentum % is 25.13% and 1327.8% above the Healthcare Providers & Services industry median of 1.76. Carlsmed's overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Carlsmed (FRA:I82), the current 3-1 Month Momentum % is 25.13% as of Sep. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Carlsmed Inc is a commercial-stage medical technology company focused on developing AI-enabled personalized solutions for spine surgery. The company operates as a single operating and reportable segment engaged in the design, manufacture, and marketing of its Aprevo technology platform, which provides customized surgical planning and implants for lumbar and cervical spine fusion procedures, mainly sold to hospitals and ambulatory surgical centers.
12GF Score
Get the complete analysis for FRA:I82
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:I82 has been successfully added to your 
